<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Dr. Reddys Laboratories</title>
	<atom:link href="http://www.stockbloghub.com/tag/dr-reddys-laboratories/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Tue, 22 May 2012 18:53:06 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(GSK) Pharma Majors to Gain from India</title>
		<link>http://www.stockbloghub.com/2009/08/19/gsk-pharma-majors-to-gain-from-india/12677</link>
		<comments>http://www.stockbloghub.com/2009/08/19/gsk-pharma-majors-to-gain-from-india/12677#comments</comments>
		<pubDate>Wed, 19 Aug 2009 22:21:16 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Dr. Reddys Laboratories]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Merck & Company Inc.]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[RDY]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[WYE]]></category>
		<category><![CDATA[Wyeth]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=12677</guid>
		<description><![CDATA[All major pharmaceutical companies that have operations in India are likely to benefit from the latest decision made by the Commerce Ministry in that country. The ministry accepted the Mashelkar committee’s report, according to which India will continue to allow patents on incremental innovations if the enhancements are beneficial to patients. The decision was taken amidst severe protests from generic players and health activists who fear this will not allow cheaper generic drugs to enter the market. On the basis of 2008 sales figures, the Indian pharmaceutical market ranks 13th in the world, with sales of $7.7bn last year (an increase of 4% over 2007). The rapidly growing middle income group with higher disposable income makes it an attractive place for major pharma companies. The pharmaceutical market is expected to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/19/gsk-pharma-majors-to-gain-from-india/12677/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SGP) Schering-Plough Settles Lawsuits &#8211; Analyst Blog</title>
		<link>http://www.stockbloghub.com/2009/08/12/sgp-schering-plough-settles-lawsuits-analyst-blog/12445</link>
		<comments>http://www.stockbloghub.com/2009/08/12/sgp-schering-plough-settles-lawsuits-analyst-blog/12445#comments</comments>
		<pubDate>Thu, 13 Aug 2009 00:22:55 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Caraco Pharmaceutical Laborato]]></category>
		<category><![CDATA[CPD]]></category>
		<category><![CDATA[Dr. Reddys Laboratories]]></category>
		<category><![CDATA[GeoPharma Inc.]]></category>
		<category><![CDATA[GORX]]></category>
		<category><![CDATA[Merck & Company Inc.]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[Perrigo Company]]></category>
		<category><![CDATA[PRGO]]></category>
		<category><![CDATA[RDY]]></category>
		<category><![CDATA[Schering-Plough Corp.]]></category>
		<category><![CDATA[SGP]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=12445</guid>
		<description><![CDATA[Yesterday, Schering-Plough Corp. (SGP) said it has signed an agreement with Orchid Chemicals &#38; Pharmaceuticals Ltd. and Orgenus Pharma Inc., which sought to make generic versions of its allergy drug Clarinex. This signals the end of all pending litigations that Schering filed against several generic drug manufacturing companies in the US District Court of New Jersey since 2006. These companies wanted to market solid oral doses of the drug, desloratadine, in the U.S. as generic brands before the expiration of certain Schering patents. Pursuant to the agreement, Orchid received rights to launch a generic version of the Clarinex brand Reditabs in the U.S. on Jan. 1, 2012 and Clarinex brand 5 milligram tablets on July 1 of that year. Schering holds various patents related to Clarinex till 2022. Schering has ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/12/sgp-schering-plough-settles-lawsuits-analyst-blog/12445/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(RDY) Dr. Reddy&#8217;s Lab Ltd. &#8211; Momentum &#8211; Zacks Rank Buy</title>
		<link>http://www.stockbloghub.com/2009/07/01/dr-reddys-lab-ltd-momentum-zacks-rank-buy/9234</link>
		<comments>http://www.stockbloghub.com/2009/07/01/dr-reddys-lab-ltd-momentum-zacks-rank-buy/9234#comments</comments>
		<pubDate>Wed, 01 Jul 2009 23:22:56 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Dr. Reddys Laboratories]]></category>
		<category><![CDATA[RDY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=9234</guid>
		<description><![CDATA[Dr. Reddy&#8217;s Lab Ltd. (RDY) doubled its sales from last year in its most recently reported quarter, sending its share price higher by more than 100% in just the last 3 months. Company Description Dr. Reddy&#8217;s, together with its subsidiaries, specializes in developing pharmaceutical and medical technology. The company focuses on drug discovery, generics and care products and has a market cap of $2.8 billion. Fourth-Quarter Results Dr. Reddy&#8217;s reported fourth-quarter results on May 18 that were very solid but impaired by one-time charges. Sales were up big, climbing 50% from last year to $407 million. When stripping out one-time items related to a German subsidiary, earnings came in at 48 cents per share, 15 cents ahead of the consensus. Generics Drive Growth The company noted that its sales growth ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/07/01/dr-reddys-lab-ltd-momentum-zacks-rank-buy/9234/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

